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OCT as a window to the MS brain
The view becomes slightly clearer
Optical coherence tomography (OCT) has been
applied to multiple sclerosis (MS) to investigate reti-
nal neuroaxonal loss. Reductions in peripapillary ret-
inal nerve fiber layer (pRNFL) thickness have been
reported in different MS-related subtypes from clini-
cally isolated syndromes1 to secondary progressive
MS.2 A recent meta-analysis additionally confirmed
atrophy of the ganglion cell–inner plexiform (GCIP)
layer in MS.3 Associations between OCT-derived ret-
inal thicknesses (pRNFL and GCIP) and cerebral
atrophy quantified by MRI have also been reported,4,5
leading to the suggestion of usingOCT as a biomarker
of MS disease progression in the clinic. Despite chal-
lenges and lingering questions, several recent studies
suggest potential for clinical value. For example,
a recent retrospective study provided evidence for
differential rates of GCIP atrophy according to
DMT usage. Natalizumab-treated patients with MS
exhibited the lowest atrophy rates (20.16 mm/y),
similar to healthy controls (20.14 mm/y), whereas
those treated with interferon-b and glatiramer acetate
had more atrophy (20.28 to 20.54 mm/y).6 An ear-
lier study found faster GCIP annualized thinning
rates associated with clinical or radiologic MS activity
in 161 patients.7 In addition, a recent cohort study
identified a cutoff of 88 mm for the pRNFL to predict
twice the risk of disability worsening at 2 years and 4
times higher risk at 5 years for the patients (many
being treated) below this cutoff.8 This literature im-
plies a potential role for OCT in the clinical moni-
toring of MS in the future.
In this issue of Neurology®, Pisa et al.9 extend this
work by determining OCT associations with no evi-
dence of disease activity (NEDA) in MS. NEDA has
been suggested as a long-term treatment goal in MS.
Conventionally applied to active MS amenable to
disease-modifying treatments (DMTs), it relies upon
3 criteria being concurrently met: no clinical relapse,
no disability worsening, and no new MRI activity (no
new/enlarging T2 lesions and no gadolinium-
enhancing lesions). Pisa et al. performed a longitudi-
nal investigation of 72 patients with MS, performing
MRI, OCT, visual evoked potentials, and Expanded
Disability Status Scale (EDSS) assessments, 2 years
apart. Patients with MS with NEDA at follow-up
(31.7%) had mean binocular RNFL thinning of
20.93 mm 6 1.35 SD, whereas patients with evi-
dence of disease activity (EDA) demonstrated greater
RNFL thinning at 22.83 mm 6 2 SD (t test p ,
0.001). There was no interaction between NEDA/
EDA and disease subtype (relapsing vs progressive).
Further analyses showed RNFL loss when MRI activ-
ity or relapse activity were considered separately.
Greater RNFL loss over 2 years was also associated
with worsening EDSS scores. After receiver operating
characteristic curve calculation, a value of 21.25 mm
was obtained as the optimal cutoff value associated
with NEDA status, with specificity 81.4% and sen-
sitivity 80%. A history of optic neuritis did not appear
to alter the longitudinal changes in RNFL thinning.
In the clinic, how would recording serial changes
in OCT add value to clinical assessment and MRI?
Certain challenges remain for OCT (e.g., determin-
ing its contribution to clinical monitoring over a real-
istic time frame, its value in the presence of optic
nerve or radiation lesions). Therefore, large prospec-
tive studies are required, in which OCT metrics are
used as risk factors for disease worsening. For exam-
ple, the Rio criteria established that in the first year
of starting a new therapy, a higher composite score,
which includes relapses, disability worsening, and
.2 T2 lesions, is associated with higher risk of dis-
ability worsening over the next 2 years.10 Analo-
gously, OCT could be validated within a composite
score of several predictors of MS clinical progression.
However, we first need to understand the critical
threshold for OCT metrics, and how this interacts
with our other markers for disability worsening.
Multicenter, international clinical repositories with
long-term follow-up could be leveraged to derive
and validate thresholds and interactions for OCT
and other early disease markers. Once we understand
how OCT fits with our established predictors, one
would next need to know the effectiveness of treat-
ment escalation upon long-term MS outcomes for
disability. As an example, if a patient was stable from
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a clinical and imaging perspective, what would be the
long-term benefit of a more effective therapy if the
patient demonstrated a sustained annual retinal thin-
ning of some validated threshold?
Overall, this study provides interesting insights
into the potential utility of OCT for monitoring
MS disease activity. Some limitations to this study
exist, such as the requirement to validate in an inde-
pendent cohort, the limited sample size and follow-
up, and lack of a normative reference population for
defining the spontaneous decline of retinal thickness
with age. Moreover, the cutoff proposed is based on
the change in RNFL and not on a specific absolute
value such as in previous studies and for this reason
these results cannot be considered a validation of pre-
vious biomarkers. Nevertheless, the findings of this
study lend support to the notion that OCT is related
to inflammatory activity, presumably through an
indirect mechanism that affects neuroaxonal loss.
Future studies should be able to address the outstand-
ing issues related to its potential utility in MS for
monitoring disease progression and even, perhaps,
guide therapy decision-making. However, these stud-
ies will require multicenter collaborations with large
enough patient numbers and data of sufficient dura-
tion to inform long-term, accurate predictions. This
will be a large research endeavor; nevertheless, the
findings from this current study provide us with
impetus and encouragement to pursue this goal.
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